本人黄建春，作为上海雪榕生物科技股份有限公司（以下简称"公司"）的独 立董事，在2023年度严格按照《公司法》《上市公司独立董事管理办法》《深圳 证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》等法律 法规、规范性文件以及《公司章程》《公司独立董事工作制度》的规定和要求， 认真、勤勉、独立的履行独立董事职责，主动了解公司的生产经营运作情况，积 极出席公司召开的相关会议，认真审议董事会的各项议案，充分发挥了独立董事 的独立性、专业性的作用，切实维护了公司和全体股东尤其是中小股东的合法权 益。现将本人2023年度履行独立董事职责情况汇报如下： 上海雪榕生物科技股份有限公司 2023 年度独立董事述职报告 各位股东及股东代表： 一、独立董事的基本情况 （一）个人工作履历、专业背景等情况 黄建春，男，1964 年 5 月生，中国国籍，无境外永久居留权，本科学历， 在职硕士。曾任上海食用菌技术推广站技术科副科长、农艺师，上海市农业技术 推广服务中心高级农艺师、推广研究员。现任公司独立董事、上海市农业科学院 食用菌研究所研究员、上海园艺学会副理事长。 （二）是否存在影响独立性的情况说明 报告期内，本人任职 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 上海雪榕生物科技股份有限公司（以下简称"公司"）于 2024 年 4 月 25 日召 开第五届董事会第九次会议和第五届监事会第七次会议，审议通过了《关于 2023 年度计提存货跌价值准备的议案》。现将具体情况公告如下： 一、本次计提存货跌价准备的情况概述 | 证券代码：300511 | 证券简称：雪榕生物 公告编号：2024-027 | | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | 上海雪榕生物科技股份有限公司 关于 2023 年度计提存货跌价准备的公告 （一）本次计提存货跌价准备的原因 为了能公允地反映公司截至 2023 年 12 月 31 日的财务状况和资产价值，使 公司的会计信息更具有合理性，根据《企业会计准则》《深圳证券交易所上市公 司自律监管指引第 2 号——创业板上市公司规范运作》等相关规定的要求，基于 谨慎性原则，公司对合并报表范围内截至 2023 年 12 月 31 日存在可能发生减值 迹象的资产进行全面清查和减值测试后，决定计提存货跌价准备共计人民币 58, ...

上海雪榕生物科技股份有限公司 董事会审计委员会对会计师事务所 2023 年度履职情况评估 及履行监督职责情况的报告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 根据《公司法》《证券法》《上市公司治理准则》《深圳证券交易所上市公司 自律监管指引第 2 号——创业板上市公司规范运作》和《公司章程》等规定和 要求，上海雪榕生物科技股份有限公司（以下简称"公司"）董事会审计委员会 本着勤勉尽责的原则，恪尽职守，认真履职。现将董事会审计委员会对会计师 事务所安永华明会计师事务所（特殊普通合伙）（以下简称"安永华明"）2023 年 度履职评估及履行监督职责的情况汇报如下： 一、2023 年年审会计师事务所基本情况 （一）会计师事务所基本情况 | 证券代码：300511 | 证券简称：雪榕生物 公告编号：2024-030 | | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | 在执行审计工作的过程中，安永华明就会计师事务所和相关审计人员的独 立性、审计工作小组的人员构成、审计计划、风险判断、风险及舞弊的测试和 评价方法、年度审计重点、审计 ...

上海雪榕生物科技股份有限公司 已审财务报表 2023年度 上海雪榕生物科技股份有限公司 目 录 | | | 页 次 | | | --- | --- | --- | --- | | 一、审计报告 | 1 – | | 7 | | 二、已审财务报表 | | | | | 合并资产负债表 | 8 | – | 10 | | 合并利润表 | 11 | – | 12 | | 合并股东权益变动表 | 13 | – | 14 | | 合并现金流量表 | 15 | – | 16 | | 公司资产负债表 | 17 | – | 18 | | 公司利润表 | | 19 | | | 公司股东权益变动表 | 20 | – | 21 | | 公司现金流量表 | 22 | – | 23 | | 财务报表附注 | 24 | – | 123 | | 补充资料 | | | | | 1. 非经常性损益明细表 | | 1 | | | 2. 净资产收益率和每股亏损 | | 2 | | 审计报告 安永华明（2024）审字第70009152_B01号 上海雪榕生物科技股份有限公司 上海雪榕生物科技股份有限公司全体股东： 一、审计意见 我们审计了上海雪榕生物科技 ...

| 证券代码：300511 | 证券简称：雪榕生物 | 公告编号：2024-037 | | --- | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | | 上海雪榕生物科技股份有限公司 关于使用部分闲置自有资金进行现金管理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 上海雪榕生物科技股份有限公司(以下简称"公司"）于 2024 年 4 月 25 日 召开第五届董事会第九次会议及第五届监事会第七次会议，审议通过了《关于使 用部分闲置自有资金进行现金管理的议案》，同意在保证日常经营运作资金需求、 有效控制投资风险的情况下，使用额度不超过 2.5 亿元的暂时闲置自有资金购买 安全性高、流动性好、风险性低的理财产品，在上述额度内，资金可以滚动使用， 期限为自董事会审议通过之日起不超过 12 个月。具体内容如下： 一、使用暂时闲置自有资金进行现金管理的基本情况 1、投资目的 （1）尽管公司购买安全性高、流动性好、风险性低的理财产品，但金融市场 受宏观经济的影响较大，不排除该项投资受到市场波动的影响。 为充分利用闲置资金、提高资金 ...

国投证券股份有限公司 关于上海雪榕生物科技股份有限公司 2023 年度募集资金存放与使用情况的专项核查报告 根据《证券发行上市保荐业务管理办法》《深圳证券交易所创业板股票上市 规则》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 等有关规定，国投证券股份有限公司（以下简称"国投证券"或"本保荐机构"） 作为上海雪榕生物科技股份有限公司（以下简称"雪榕生物"或"公司"）创业 板向特定对象发行股票的保荐机构，对雪榕生物 2023 年度募集资金存放和使用 情况进行了专项核查，现将核查情况报告如下： 一、募集资金基本情况 经中国证监会《关于同意上海雪榕生物科技股份有限公司向特定对象发行股 票注册的批复》（证监许可【2021】881 号）核准，公司于 2022 年 3 月 4 日向 11 名特定对象发行人民币普通股（A 股）65,676,567 股，发行价格为人民币 6.06 元 /股，募集资金总额为人民币 397,999,996.02 元，扣除与本次发行有关费用人民币 10,519,671.82 元（含增值税）后，实际 ...

Financial Performance - The company achieved operating revenue of CNY 2,062.83 million in 2021, a decrease of 6.33% year-on-year[13]. - The net profit attributable to shareholders was CNY -292.07 million, representing a decline of 226.76% compared to the previous year[13]. - The net profit after deducting non-recurring gains and losses was -¥29.0 million in 2021, a decrease of 230.53% compared to a profit of ¥22.2 million in 2020[30]. - The weighted average return on net assets was -15.88%, a decrease of 28.41% from the previous year[20]. - The company's total assets decreased by 4.57% to CNY 4,340.13 million at the end of 2021[19]. - The net cash flow from operating activities was CNY 246.75 million, down 55.58% from the previous year[20]. - The net profit attributable to shareholders was ¥101.4 million in Q1, but turned negative in subsequent quarters, with Q2 at -¥172.1 million, Q3 at -¥44.7 million, and Q4 at -¥176.7 million[21]. - The net cash flow from operating activities showed a significant recovery, with Q1 at ¥94.2 million, Q3 at ¥19.2 million, and Q4 surging to ¥175.8 million[21]. - The asset-liability ratio increased to 61.88% in 2021 from 55.89% in 2020, indicating a rise of 5.99%[30]. - The EBITDA to total debt ratio fell to 2.43% in 2021 from 23.90% in 2020, reflecting a decline of 21.47%[30]. - The interest coverage ratio dropped significantly to -2.84 in 2021 from 3.28 in 2020, a decrease of 186.59%[30]. Dividend and Shareholder Information - The company reported a cash dividend of 0.00 yuan per 10 shares for all shareholders, with no bonus shares issued, based on a total of 507,600,151 shares[1]. - The top shareholder, Yang Yongping, holds 24.29% of the shares, amounting to 107,365,050 shares[22]. - The company has no preferred shareholders as of the report date[24]. Business Operations and Strategy - The company operates modern agricultural enterprises focused on the research, cultivation, and sales of edible mushrooms, with production facilities in multiple regions including Jilin, Shandong, Guangdong, Sichuan, Guizhou, Gansu, and Thailand[3]. - Key products include Enoki mushrooms, King oyster mushrooms, Shiitake mushrooms, and others, emphasizing high quality and safety in food production[5]. - The sales model primarily involves distributors, with direct sales to supermarkets, chain restaurants, and fresh food delivery platforms, utilizing a buyout sales approach[9]. - The pricing strategy includes weekly market analysis for existing products and comprehensive market research for new product pricing, ensuring competitive positioning[10]. - The company has implemented a credit policy for large and quality customers, resulting in low accounts receivable balances[10]. - The company emphasizes the mechanization, standardization, and year-round production of edible mushrooms, significantly saving land resources[3]. - The company aims to enhance its market presence through continuous product innovation and expansion into new regions[3]. - The company has established a nationwide sales network to enhance market responsiveness and customer retention[17]. - The competitive landscape in the edible mushroom industry has intensified, leading to a general decline in profitability across the sector in 2021[17]. Audit and Compliance - The company has transitioned its auditing firm to Ernst & Young Huaming, receiving a standard unqualified audit opinion for the financial report[1]. Project Losses - The company reported a significant loss of CNY 4,850.09 million from its Thailand project, with a loss attributable to shareholders of CNY 2,910.05 million[13]. Quarterly Performance - In Q1 2021, the company reported revenue of ¥566.5 million, while Q2 revenue dropped to ¥362.3 million, followed by Q3 at ¥500.5 million, and Q4 at ¥633.5 million[21].

Financial Performance - The company's revenue for Q1 2021 was ¥566,499,913.52, a decrease of 5.72% compared to ¥600,852,768.17 in the same period last year[8] - Net profit attributable to shareholders was ¥101,367,147.34, down 40.30% from ¥169,805,933.35 year-on-year[8] - The net profit after deducting non-recurring gains and losses was ¥84,346,680.30, reflecting a 51.98% decline from ¥175,658,147.06 in the previous year[8] - Basic earnings per share decreased by 40.00% to ¥0.24 from ¥0.40 in the previous year[8] - Diluted earnings per share fell by 45.00% to ¥0.22, down from ¥0.40 year-on-year[8] - The weighted average return on equity was 4.90%, down 4.40% from 9.30% in the same period last year[8] - The total comprehensive income for Q1 2021 was CNY 93,107,824.21, a decrease of 42.55% from CNY 162,024,727.12 in Q1 2020[52] - The operating profit for Q1 2021 was CNY 88,914,090.49, down 47.36% from CNY 168,939,525.68 in the same period last year[54] Cash Flow and Assets - The net cash flow from operating activities was ¥94,171,489.26, a significant drop of 55.16% compared to ¥210,012,722.59 in the same quarter last year[8] - Cash and cash equivalents decreased by 40.50% to 452.10 million yuan, primarily due to loan repayments and funding for investment projects[18] - The company's cash flow from operating activities for Q1 2021 was CNY 94,171,489.26, a significant decrease of 55.19% compared to CNY 210,012,722.59 in Q1 2020[59] - Total assets at the end of the reporting period were ¥4,523,132,192.42, a slight decrease of 0.54% from ¥4,547,783,435.53 at the end of the previous year[8] - Total cash and cash equivalents at the end of the period amounted to 455,792,498.39 CNY, down from 510,734,470.23 CNY in the previous period[60] Expenses and Costs - Total operating costs increased to CNY 497,618,778.68 from CNY 434,113,698.18, with operating costs specifically rising to CNY 432,067,920.20 from CNY 368,984,797.21[50] - Research and development expenses increased by 58.03% to 47.59 million yuan, reflecting higher investment in R&D activities[18] - The financial expenses for Q1 2021 were CNY 10,871,686.12, which is a significant increase compared to CNY 4,819,068.21 in Q1 2020[54] - The company reported a decrease in sales expenses to CNY 3,618,995.52 from CNY 5,186,929.58 in the previous year, reflecting a reduction of 30.29%[54] Market and Competition - The company anticipates intensified market competition leading to potential price declines in its products, prompting a strategy to enhance marketing efforts and brand recognition[20][21] - The company faces risks of declining gross margin and profits due to increased competition in the domestic edible mushroom market and potential underperformance of its overseas production base in Thailand[23] Investments and Projects - The company established a joint venture, Shanghai Rongshang Food Co., Ltd., with a 60% ownership stake, to enhance its market presence[27] - The project for the Thai edible mushroom factory has not yet commenced, with no funds allocated to it so far[31] - The company has achieved 62.93% of the investment progress for the Dezhou daily production project, with 6.67 million RMB invested out of 25 million RMB planned[31] Regulatory Compliance - The company received approval from the China Securities Regulatory Commission for a specific stock issuance, indicating compliance with regulatory requirements[28] - The company has not reported any non-operating fund occupation by controlling shareholders or related parties during the reporting period[35] - There were no violations regarding external guarantees during the reporting period[34] Risks and Challenges - Seasonal fluctuations in sales prices and profits are expected, with the first and fourth quarters typically yielding higher prices due to increased demand[22] - The main raw materials, including rice bran and corn husks, are subject to quality and price fluctuations, which could adversely affect the company's gross margin if not managed effectively[24] - Despite a controlled cultivation model ensuring food safety, there are still risks of contamination during raw material procurement and inventory management[26] - The expansion of production capacity and business scale may lead to management risks, prompting the company to implement a partner mechanism to enhance management efficiency[25]

上海雪榕生物科技股份有限公司 募集资金存放与使用情况鉴证报告 2023年度 上海雪榕生物科技股份有限公司 目 录 | | | 页 次 | | --- | --- | --- | | 一、 | 关于上海雪榕生物科技股份有限公司 | | | | 2023年度募集资金存放与使用情况专项鉴证报告 | 1 - 2 | | 二、 | 上海雪榕生物科技股份有限公司 | | | | 关于2023年度募集资金存放与使用情况的专项报告 | 3 - 12 | 关于上海雪榕生物科技股份有限公司 2023年度募集资金存放与使用情况鉴证报告 安永华明（2024）专字第70009152_B02号 上海雪榕生物科技股份有限公司 上海雪榕生物科技股份有限公司董事会： 我们接受委托，对后附的上海雪榕生物科技股份有限公司2023年度募集资金存放 与使用情况的专项报告（"募集资金专项报告"）进行了鉴证。按照《上市公司监管 指引第2号——上市公司募集资金管理和使用的监管要求》、《深圳证券交易所上市公 司自律监管指引第2号——创业板上市公司规范运作》及相关格式指南编制募集资金专 项报告，并保证其内容真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏 ...

一、董事会会议召开情况 | 证券代码：300511 | 证券简称：雪榕生物 公告编号：2024-025 | | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | 上海雪榕生物科技股份有限公司 第五届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 1、本次董事会由董事长杨勇萍先生召集，会议通知于 2024 年 4 月 12 日以 电子邮件等通讯方式发出。 2、本次董事会于 2024 年 4 月 25 日在上海雪榕生物科技股份有限公司（以 下简称"公司"）会议室召开，采取现场和通讯相结合的方式进行表决。 3、本次会议应出席董事 7 人，实际出席董事 7 人。 4、本次董事会由董事长杨勇萍先生主持，公司监事、高级管理人员和公司 保荐代表人聂晓春女士、黄璇女士列席了本次董事会。 5、本次董事会会议的召集、召开和表决程序符合《公司法》等法律、法规 及《公司章程》的有关规定，合法有效。 二、董事会会议审议情况 1、审议通过《关于 2023 年总经理工作报告的议案》 本议案以 7 票同意，0 票反对，0 票弃权获得通过 ...